RecruitingEarly Phase 1NCT04600115

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)


Sponsor

University of Utah

Enrollment

100 participants

Start Date

Mar 3, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adenosine, a medical device called MRI, and others for people with mri scans. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdenosine

Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion

DRUGRegadenoson

0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.

DRUGO-15 labeled radioactive water

O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging

DEVICEMRI

Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson

DEVICEPET Imaging

Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day


Locations(1)

university of Utah, Radiology Research

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04600115